Literature DB >> 487620

Measurement of 1,25-dihydroxycholecalciferol in man by radioimmunoassay.

T L Clemens, G N Hendy, S E Papapoulos, L J Fraher, A D Care, J L O'Riordan.   

Abstract

1 alpha, 25-Dihydroxycholecalciferol (1,25-(OH)2D3) has been measured in human serum by radioimmunoassay. The assay uses a high titre antiserum raised in sheep against 1,25-(OH)2D3-25-hemisuccinate, conjugated to bovine serum albumin. The sensitivity of the assay is 10 pg/tube. Other hydroxylated forms of vitamin D3 cross react with the antiserum and are therefore removed from serum extracts by chromatography on Sephadex LH 20 followed by high pressure liquid chromatography. The mean (+/- SEM) serum 1,25-(OH)2D3 concentration for a group of healthy adult subjects was 41 +/- 2.5 pg/ml. None was detected in anephric patients and the concentration was low or undetectable in patients with chronic renal failure.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 487620     DOI: 10.1111/j.1365-2265.1979.tb03068.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  11 in total

1.  A case of resolving idiopathic hypoparathyroidism.

Authors:  L Ostlere; J Reeve
Journal:  Postgrad Med J       Date:  1991-02       Impact factor: 2.401

2.  Incomplete suppression of parathyroid hormone activity in sarcoidosis presenting with hypercalcaemia.

Authors:  R R Ghose; J S Woodhead; R C Brown
Journal:  Postgrad Med J       Date:  1983-09       Impact factor: 2.401

3.  Simultaneous measurement of 1.25-dihydroxy-vitamin D, 24.25-dihydroxy-vitamin D and 25-hydroxy-vitamin D from a single two milliliters serum specimen. Preliminary clinical application.

Authors:  D Tartarotti; S Adami; G Galvanini; R Dorizzi; G Piemonte; V Lo Cascio
Journal:  J Endocrinol Invest       Date:  1984-12       Impact factor: 4.256

4.  Hypercalcaemic sarcoidosis in hypoparathyroidism.

Authors:  T H Mitchell; T C Stamp; M V Jenkins; E B Mawer; J L Berry
Journal:  Br Med J (Clin Res Ed)       Date:  1983-03-05

5.  The relationship between serum vitamin D concentrations and in vivo tetracycline labeling of osteoid in crush fracture osteoporosis.

Authors:  E B Mawer; M E Arlot; J Reeve; J R Green; J Dattani; C Edouard; P J Meunier
Journal:  Calcif Tissue Int       Date:  1991-02       Impact factor: 4.333

6.  Effects of weight loss on serum 1,25-(OH)2-vitamin D concentrations in adults: a preliminary report.

Authors:  J Lemann; R W Gray; W J Maierhofer; N D Adams
Journal:  Calcif Tissue Int       Date:  1984-03       Impact factor: 4.333

7.  Serum vitamin D metabolites in cadmium-exposed persons with renal damage.

Authors:  K Nogawa; I Tsuritani; T Kido; R Honda; M Ishizaki; Y Yamada
Journal:  Int Arch Occup Environ Health       Date:  1990       Impact factor: 3.015

8.  Vitamin D deficiency, osteomalacia, and primary biliary cirrhosis. Response to orally administered vitamin D3.

Authors:  M Davies; E B Mawer; H J Klass; G A Lumb; J L Berry; T W Warnes
Journal:  Dig Dis Sci       Date:  1983-02       Impact factor: 3.199

9.  Vitamin D status in Crohn's disease: association with nutrition and disease activity.

Authors:  A D Harries; R Brown; R V Heatley; L A Williams; S Woodhead; J Rhodes
Journal:  Gut       Date:  1985-11       Impact factor: 23.059

10.  Regulation of calcium absorption by 1,25,dihydroxy-vitamin D--studies of the effects of a bisphosphonate treatment.

Authors:  S Adami; W B Frijlink; O L Bijvoet; J L O'Riordan; T L Clemens; S E Papapoulos
Journal:  Calcif Tissue Int       Date:  1982-07       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.